HBK Investments’s Aspire Biopharma ASBP Stock Holding History

HBK Investments’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250	Closed	-$2.99M	–	530
2022 Q2	$2.99M	Buy	+250	New	+$2.99M	0.02%	305

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HBK Investments's ASBP Position: Q3 2022 in Review

HBK Investments sold out of Aspire Biopharma (ASBP) in Q3 2022, closing a stake of 250 shares — an estimated $2.99M sold.

HBK Investments first reported a position in ASBP in Q2 2022 and held it in 1 quarter. The position peaked at $2.99M in Q2 2022. 59 funds tracked by Wall St. Rank hold ASBP as of Q3 2022.

HBK Investments reported no remaining Aspire Biopharma position as of Q3 2022 after selling out during the quarter.
HBK Investments sold 250 Aspire Biopharma shares in Q3 2022, an estimated $2.99M.
HBK Investments first reported a position in Aspire Biopharma in Q2 2022 and held it in 1 quarter.
HBK Investments's Aspire Biopharma position peaked at $2.99M in Q2 2022.
59 funds tracked by Wall St. Rank held Aspire Biopharma as of Q3 2022.

Based on HBK Investments's 13F filing for Q3 2022, filed 14 Nov 2022.